Kite Files the Industry’s First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel – Business Wire (press release)
|
Kite Files the Industry's First CAR–T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel
Business Wire (press release) This application represents the first chimeric antigen receptor (CAR) T-cell therapy submitted to the EMA. Axicabtagene ciloleucel is currently under review by the U.S. Food and Drug Administration (FDA), and the FDA has set a Prescription Drug User … |
